Moxifloxacin Dexamethasone Ophthalmic Solution Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solutions for topical administration of moxifloxacin and dexamethasone do not provide stable, preserved, multi-dose solution compositions suitable for both eye and ear applications, with existing compositions either being unstable or not effectively formulated for multi-dose use.
Innovation Solution
Aqueous compositions comprising moxifloxacin hydrochloride, dexamethasone phosphate, edetate disodium, an ionic tonicity adjusting agent, boric acid, a nonionic surfactant, and either benzalkonium chloride or sorbitol, formulated to maintain a pH of 7.5-8.1, ensuring stability and multi-dose capability for topical administration to the eye or ear.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing moxifloxacin and dexamethasone compositions are formulated, then antibiotic and anti-inflammatory therapy is provided, but the compositions are unstable or not suitable for multi-dose use
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range to 7.5-8.1 and adjusting ionic strength through specific tonicity agents. These parameter modifications enable the formulation to achieve both chemical stability and multi-dose usability, resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The patent employs composite material formulation by combining moxifloxacin hydrochloride with dexamethasone phosphate in a specific aqueous system containing edetate disodium, tonicity agents, and preservatives. This composite approach creates a stable multi-dose solution that neither component achieves alone, simultaneously improving reliability and multi-dose capability.
2Ease of operation
If moxifloxacin and dexamethasone are combined in solution form, then topical administration to eye and ear is enabled, but stability is compromised
Solution Approach 1:
The patent resolves the contradiction between ease of operation and stability by precisely controlling the pH parameter within 7.5-8.1 and adjusting ionic strength. These parameter changes enable the solution to remain stable while maintaining suitability for topical administration to both ocular and otic tissues.
Solution Approach 2:
The patent introduces edetate disodium as an intermediary chelating agent that stabilizes the combination of moxifloxacin and dexamethasone in solution. This intermediary substance prevents precipitation and degradation, enabling stable topical formulations for both eye and ear applications.
3Object-affected harmful factors
If preservatives are added to enable multi-dose use, then microbial protection is improved, but chemical stability may be affected
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range to 7.5-8.1, which enhances the effectiveness of preservatives like benzalkonium chloride while maintaining chemical stability of the active ingredients. This parameter optimization resolves the contradiction between microbial protection and chemical stability.
Solution Approach 2:
The patent uses a composite preservative system combining benzalkonium chloride with edetate disodium and specific tonicity agents. This composite approach provides effective microbial protection while the synergistic interactions maintain chemical stability, resolving the contradiction between these two requirements.
Data Source
AI summary
Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.